Takuji Yamasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takuji Yamasaki has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Masayuki Saruta
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
2 shared publications - Ryosuke Miyazaki
Division of Gastroenterology and Hepatology, Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan
2 shared publications - Toshiyuki Sakurai
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo
2 shared publications - Yuki Maruyama
Division of Gastroenterology and Hepatology, Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan
2 shared publications H Miyashita
The Jikei University, School of Medicine, Division of Gastroentelogy and Hepatology, Department of Internal Medicine
1 shared publicationHaruna Miyashita
Division of Gastroenterology and Hepatology, Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan
1 shared publication
Latest Publications
- Open Access
- 14 February 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (5) , 847-854
Prostaglandin E‐major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase
Background and Aim: Ulcerative colitis (UC) is usually detected by clinical symptoms, such as bleeding and diarrhea; however, it is rather difficult to assess during asymptomatic clinical remission (CR). Hence, there is a need for a biomarker that can reliably detect UC during remission. We previously reported on the utility of the prostaglandin E‐major urinary metabolite (PGE‐MUM) as a biomarker reflecting UC activity. In this study, we evaluated the effectiveness of the PGE‐MUM in the diagnosis of endoscopic, histological, and histo‐endoscopic mucosal remission of UC, comparing with fecal tests.Methods: This prospective study was conducted at the Jikei University Hospital between August 2017 and January 2021. Patients with UC in CR scheduled to undergo colonoscopy were included. The association between the PGE‐MUM with endoscopic remission (ER), histological remission (HR), and complete mucosal healing (CMH, defined as histo‐endoscopic remission) was analyzed. We also compared the area under the curve (AUC) for the receiver operating characteristic curves between PGE‐MUM, fecal calprotectin (FC), and fecal immunochemical test (FIT).Results: In total, 128 patients were analyzed. PGE‐MUM differed significantly in ER versus non‐ER (14.5 vs 16.7, P = 0.028), HR versus non‐HR (14.2 vs 17.4, P = 0.004), and CMH versus non‐CMH (14.3 vs 16.7, P = 0.021). There were no significant differences between the AUCs for PGE‐MUM, FC, and FIT for ER, HR, or CMH.Conclusions: The PGE‐MUM can determine CMH in UC even during CR, regardless of the disease phenotype, indicating its clinical benefit for non‐invasive monitoring.
- 14 February 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (5) , 847-854
Open AccessProstaglandin E‐major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase
Background and Aim: Ulcerative colitis (UC) is usually detected by clinical symptoms, such as bleeding and diarrhea; however, it is rather difficult to assess during asymptomatic clinical remission (CR). Hence, there is a need for a biomarker that can reliably detect UC during remission. We previously reported on the utility of the prostaglandin E‐major urinary metabolite (PGE‐MUM) as a biomarker reflecting UC activity. In this study, we evaluated the effectiveness of the PGE‐MUM in the diagnosis of endoscopic, histological, and histo‐endoscopic mucosal remission of UC, comparing with fecal tests.Methods: This prospective study was conducted at the Jikei University Hospital between August 2017 and January 2021. Patients with UC in CR scheduled to undergo colonoscopy were included. The association between the PGE‐MUM with endoscopic remission (ER), histological remission (HR), and complete mucosal healing (CMH, defined as histo‐endoscopic remission) was analyzed. We also compared the area under the curve (AUC) for the receiver operating characteristic curves between PGE‐MUM, fecal calprotectin (FC), and fecal immunochemical test (FIT).Results: In total, 128 patients were analyzed. PGE‐MUM differed significantly in ER versus non‐ER (14.5 vs 16.7, P = 0.028), HR versus non‐HR (14.2 vs 17.4, P = 0.004), and CMH versus non‐CMH (14.3 vs 16.7, P = 0.021). There were no significant differences between the AUCs for PGE‐MUM, FC, and FIT for ER, HR, or CMH.Conclusions: The PGE‐MUM can determine CMH in UC even during CR, regardless of the disease phenotype, indicating its clinical benefit for non‐invasive monitoring.
- 23 September 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 93 (3) , 766
Numerous white nodules during continuous administration of a potent gastric acid suppressor
- 23 September 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 93 (3) , 766
Numerous white nodules during continuous administration of a potent gastric acid suppressor
- 23 April 2020
- Published by Georg Thieme Verlag KG
- Vol. 52 (S 01) , ePP257
IT IS SO USEFUL TO KNOW GASTRIC CANCER RISK AT GASTRIC ENTRANCE (CARDIA) WITH THE PRESENCE OF AN EASY SIMPLE SIGN
Aims We have confused with various newly endoscopic findings (patchy redness and map-like redness etc.) after H.pylori(HP)eradication. On this time, we have found out a new other ultimate useful finding showing HP related gastritis at gastric cardia including present and post HP infection. Our aim of this study is to elucidate the possibility of judgement with only this cardiac endoscopic view about presence or absence with HP infection. Methods We have found out so useful and specific cardiac image (Whale Shark Sign: WSS) closely related to HP infection six years ago. We have examined the presence of WSS on 5, 423 cases that have been able to overview on their endoscopic profiles. The 4,939 cases their serum HP antibody titers were measured from Jan. 2012 to Oct. 2019. A total of 3,837 patients (HP positive) were enrolled. Results Mean age of patients was 51.2 years old. The positive predictive value (PPV) of WSS was surprisingly high (98.9%). According to this high PPV, we can think WSS positive cases are high risk of gastric cancer. This WSS mean that the presence of irregular gastric mucosal surface pattern and the presence of lymphoid hyperplasia, that showing HP infectious stomach. This lymphoid hyperplasia at gastric cardia were recognized small round whitish nodules on white light endoscopy. And this was more emphasized with image-enhanced endoscopy (Narrow Band Imaging: NBI), it looks like Whale Shark. It is so useful to know gastric cancer risk at gastric entrance (cardia) with the presence of an easy simple sign. This WSS sign is so simple and easy for every gastroenterologist. Conclusions We have been able to judge the presence of HP infection with only cardiac endoscopic image (WSS). Since this sign is very easy and simple, everyone will be able to judge the presence of HP infection and gastric cancer risk.
- 23 April 2020
- Published by Georg Thieme Verlag KG
- Vol. 52 (S 01) , ePP257
IT IS SO USEFUL TO KNOW GASTRIC CANCER RISK AT GASTRIC ENTRANCE (CARDIA) WITH THE PRESENCE OF AN EASY SIMPLE SIGN
Aims We have confused with various newly endoscopic findings (patchy redness and map-like redness etc.) after H.pylori(HP)eradication. On this time, we have found out a new other ultimate useful finding showing HP related gastritis at gastric cardia including present and post HP infection. Our aim of this study is to elucidate the possibility of judgement with only this cardiac endoscopic view about presence or absence with HP infection. Methods We have found out so useful and specific cardiac image (Whale Shark Sign: WSS) closely related to HP infection six years ago. We have examined the presence of WSS on 5, 423 cases that have been able to overview on their endoscopic profiles. The 4,939 cases their serum HP antibody titers were measured from Jan. 2012 to Oct. 2019. A total of 3,837 patients (HP positive) were enrolled. Results Mean age of patients was 51.2 years old. The positive predictive value (PPV) of WSS was surprisingly high (98.9%). According to this high PPV, we can think WSS positive cases are high risk of gastric cancer. This WSS mean that the presence of irregular gastric mucosal surface pattern and the presence of lymphoid hyperplasia, that showing HP infectious stomach. This lymphoid hyperplasia at gastric cardia were recognized small round whitish nodules on white light endoscopy. And this was more emphasized with image-enhanced endoscopy (Narrow Band Imaging: NBI), it looks like Whale Shark. It is so useful to know gastric cancer risk at gastric entrance (cardia) with the presence of an easy simple sign. This WSS sign is so simple and easy for every gastroenterologist. Conclusions We have been able to judge the presence of HP infection with only cardiac endoscopic image (WSS). Since this sign is very easy and simple, everyone will be able to judge the presence of HP infection and gastric cancer risk.
- 1 July 2004
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 60 (1) , 124-128
EMR of upper GI lesions when using a novel soft, irrigation, prelooped hood
- 1 July 2004
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 60 (1) , 124-128
EMR of upper GI lesions when using a novel soft, irrigation, prelooped hood